Send a Tweet
Most Popular Choices
Share on Facebook 11 Share on Twitter Printer Friendly Page More Sharing
General News    H3'ed 10/10/20

U.S. expects over 1 million COVID-19 antibody doses from Regeneron, Lilly in 2020

Quicklink Submitted By   No comments
Become a Premium Member Would you like to know how many people have read this article? Or how reputable the author is? Simply sign up for a Advocate premium membership and you'll automatically see this data on every article. Plus a lot more, too.
Follow Me on Twitter     Message Scott Baker
Become a Fan
  (80 fans)

The U.S. government expects to be able to provide at no cost more than 1 million doses of antibody treatments for COVID-19 similar to the one President Donald Trump received to treat his illness, according to a top U.S. health official on Friday.

Trump received Regeneron’s treatment last week. In a radio interview with Rush Limbaugh on Friday, Trump said he is working to get both drugs approved quickly and that he may not have recovered without the treatments he received.

Read the rest of the story HERE:

At www.reuters.com

 

Rate It | View Ratings

Scott Baker Social Media Pages: Facebook Page       Twitter Page       Linked In Page       Instagram Page

Scott Baker is a Managing Editor & The Economics Editor at Opednews, and a blogger for Huffington Post, Daily Kos, and Global Economic Intersection.

His anthology of updated Opednews articles "America is Not Broke" was published by Tayen Lane Publishing (March, 2015) and may be found here:
http://www.americaisnotbroke.net/

Scott is a former President of Common Ground-NYC (http://commongroundnyc.org/), a Geoist/Georgist activist group. He has written dozens of articles for (more...)
 

Go To Commenting
The views expressed herein are the sole responsibility of the author and do not necessarily reflect those of this website or its editors.
Follow Me on Twitter     Writers Guidelines
Contact AuthorContact Author Contact EditorContact Editor Author PageView Authors' Articles
Support OpEdNews

OpEdNews depends upon can't survive without your help.

If you value this article and the work of OpEdNews, please either Donate or Purchase a premium membership.

STAY IN THE KNOW
If you've enjoyed this, sign up for our daily or weekly newsletter to get lots of great progressive content.
Daily Weekly     OpEdNews Newsletter
Name
Email
   (Opens new browser window)
 

To View Comments or Join the Conversation: